Veteran entrepreneur and molecular medical geneticist appointed
as Transformative Biotech's Co-CEO and Director
BOULDER, Colo., May 15, 2024 /PRNewswire/ -- Transformative
Biotech, LLC (T-Bio), a molecular diagnostics technology company,
today announced the appointment of Dr. Barbara Handelin as Co-CEO and to its Board of
Directors. Transformative Biotech, LLC is a licensing firm enabling
the transition of PCR from a laboratory-based technology to an
@ANYWHERE technology for the detection of infectious diseases and
cancer.
Veteran entrepreneur and molecular medical
geneticist, Dr. Handelin appointed as Transformative Biotech's
Co-CEO.
Dr. Handelin will share the CEO role with Russ Hullet, a co-founder of Transformative
Biotech. Dr. Handelin, who helped to found Integrated Genetics DNA
Diagnostic Labs in 1987 as the world's first commercial clinical
genetics testing lab, brings 35 years of experience in genetic
disease diagnostics.
"Having been active in the nascent days of the clinical use of
PCR technology, it is thrilling to join Transformative Biotech as
they introduce possibly the most impactful development in this
fundamental technology since its invention. Eliminating DNA
extraction as a required step before PCR reactions could have a
clinical impact similar to the first self-administered pregnancy
tests or the first automated blood chemistry instruments. These
developments lessened or removed the need for professional lab
technologists to prepare human medical samples before testing while
maintaining accuracy and reliability. In the same way this was
democratizing and so will "direct-to-PCR" be for analyzing DNA for
applications in medicine, agriculture, military, public health, and
veterinary medicine," said Dr. Handelin. Her full bio can be found
on Transformative Biotech's Team Page.
Handelin will assume co-executive leadership with CEO
Russ Hullet, providing strategic
leadership to the T-Bio team to complement Hullet's operational
lead role. The company is pursuing a licensing business model to
enable the broadest uptake of direct-to-PCR worldwide. T-Bio is
also piloting @Anywhere devices for infectious diseases, wherein
saliva samples can be used directly to detect viruses and bacteria.
"We are focusing on highest unmet needs in viral infection
detection where personal, rapid and sensitive test results are
critical for protecting against societal spread," says the
company's Executive Chair, Bob
Blomquist. "Home testing for COVID-19 helped individuals to
manage their own exposures; the world has learned that this is now
an essential public health tool."
"Sexually transmitted diseases and common upper respiratory
viral diseases are areas of great unmet need for rapid, highly
accurate detection," Handelin adds. "This is as exciting as when
multiplex PCR testing met the needs of testing for complex genetic
disorders such as Cystic Fibrosis and then cancer in the 1990s as
our understanding of human genetics exploded."
"I am honored that Barbara, with such a deeply relevant career,
has high confidence in our technologies and venture. Her role will
be instrumental in driving our success," said Russ Hullet, Co-CEO.
About Transformative Biotech
Transformative Biotech is
a startup biotechnology company focused on deploying its rapid,
highly accurate, direct-to-PCR technologies with the power to
transform molecular testing for infectious diseases and cancer.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transformative-biotech-welcomes-dr-barbara-handelin-as-co-ceo-302146777.html
SOURCE Transformative Biotech, LLC